The Chairman and CEO of FogPharma describes the progress the company has made this year, including on the lead β-catenin/TCF4 inhibitor program, and a partnership on an alpha-particle radioligand platform. Plus, leadership advice and how technology has changed science.
Brought to you by:
Also look for unique social pages for BiotechTV U.
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.
.png){kind=logo}
